AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the presentation of two abstracts at the upcoming American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting. The abstracts report new data from research-stage retinal studies of novel AAV vectors to support clinical phase product release for the X-linked retinitis pigmentosa (XLRP) clinical Phase 2/3 Vista study and manufacturing process improvements for future clinical trials. The ASGCT Annual Meeting is being held virtually May 11-14, 2021.
Title: Expression Assay Development for rAAV Vector Encoding Retinitis Pigmentosa GTPase Regulator (RPGRco)
Title: Subretinal Rd9 Mouse Study to Compare RPGR Expression Pre- and Post-Manufacturing Process Improvements
Abstracts for the presentations can be viewed online at: https://annualmeeting.asgct.org/.